Edwards Lifesciences

According to Deutsche Bank, Edwards Lifesciences (NYSE: EW) transcatheter heart valve (THV) sales were $72.7M (inclusive of $2-$3M in stocking) and were ahead of DB est of $68M. Deutsche Bank said that sales were also higher than 4Q10's $65.3M (which included $3-4M in stocking) and well ahead of...

Deutsche Bank has raised the price target on Edwards Lifesciences (NYSE: EW) from $82 to $85 and maintains its Hold rating.

JP Morgan has raised the price target on Edwards Lifesciences (NYSE: EW) from $76 to $78 and maintains its Underweight rating.

Wedbush Securities has raised the price target on Edwards Lifesciences (NYSE: EW) from $68 to $75 and maintains its Underperform rating.

“We believe the share price will rise in absolute terms over the next 60 days,” Morgan Stanley wrote in a report this morning regarding Edwards Lifesciences Corp. (NYSE: EW). :Edwards will present key data from the PARTNER Cohort A trial at the American College of Cardiology meeting in New Orleans...

JP Morgan has published a research report on Edwards Lifesciences (NYSE: EW) and introduces 2011 quarterly estimates on the company. In the report, JP Morgan writes "For 2011, we now expect total revenues of $1.639B (+13.6% reported, 11.8% organic), up slightly from $1.636B previously. Our...

JP Morgan has raised the price target on Edwards Lifesciences (NYSE: EW) from $66 to $74.

This morning, Citigroup said that it believes Edwards Lifesciences' (NYSE: EW) QoL data will be successful (and show a stat. signif. improvement for TAVI), “but QoL studies are open to interpretation and need to be viewed in conjunction with clinical data (which was obviously positive).” Going...

Rodman & Renshaw has upgraded Edwards Lifesciences (NYSE: EW) from Market Underperform to Market Perform. Edwards Lifesciences closed Friday at $67.91.

RBC Capital Markets has reiterated ratings and issued price target changes for the following: Jabil Circuit Inc. (NYSE: JBL) Outperform, from $22 to $18 Edwards Lifesciences (NYSE: EW) Outperform, from $60 to $77 Copart Inc. (NASDAQ: CPRT) Sector Perform, from $39 to $36 Baidu.com Inc. (NASDAQ:...

Citigroup writes for Edwards Lifescinces (NYSE: EW) that the "PARTNER Cohort B trial data forms the basis for the company's PMA filing and we believe SAPIEN will be approved by the FDA in 2H11. Now that the primary endpoint hurdles have been met, we believe the investment debate will shift to...

JP Morgan writes for Edwards Lifesciences (NYSE: EW) "[O]ur new $61 [up from $53] Dec 2010 price target is based on our DCF valuation and corresponds to a 29x multiple on our 2011 earnings estimate. This represents a significant premium to the current SMID-cap Medtech average NTM P/E of 15.4x,...

Initiation coverage from Deutsche Bank for September 10 is as follows: St. Jude Medical (NYSE: STJ) Initiate with Hold Rating and $39 price target Boston Scientific (NYSE: BSX) Initiate with Hold rating and $6.30 price target. Zimmer Holdings (NYSE: ZMH) Initiate with Hold rating and $53 price...

St. Jude Medical (NYSE: STJ) Initiate with Hold Rating and $39 price target Boston Scientific (NYSE: BSX) Initiate with Hold rating and $6.30 price target. Zimmer Holdings (NYSE: ZMH) Initiate with Hold rating and $53 price target CareFusion Corporation (NYSE: CFN) Initiate with Hold rating and $23...